Rheumatoid Arthritis News

    Skip to content
    • Home
    • Treatments
      • Tofacitinib (Xeljanz)
    • Experimental Treatments
      • Piclidenoson
      • Kevzara (Sarilumab)
      • Baricitinib (Olumiant)
    • About Us
    • Contact Us
    •
      June 12, 2017June 12, 2017

      Diplomat Pharmacy Begins Dispensing Kevzara to Treat Rheumatoid Arthritis

      Diplomat Pharmacy has begun filling prescriptions for Kevzara (sarilumab) for patients with moderate to severe rheumatoid arthritis (RA). The announcement comes after the U.S. Food and ... Read more
    • June 7, 2017June 7, 2017

      Filgotinib Improves RA Patient Outcomes When Methotrexate Is Inadequate, Study Suggests

      Active rheumatoid arthritis (RA) patients whose response to methotrexate (MTX) therapy was insufficient showed improvement when MTX was combined with filgotinib, an investigational JAK–1 inhibitor, ... Read more
    • June 5, 2017June 5, 2017

      EMA Accepts Humira and Remicade Biosimilars for Regulatory Review

      The European Medicines Agency (EMA) has accepted a marketing authorization application from generic pharmaceuticals developer Sandoz for the review of biosimilars for AbbVie’s Humira (adalimumab) and Janssen’s Remicade ... Read more
    • June 2, 2017June 2, 2017

      DMARDs Triple Therapy Provides Better Cost-Effective First Line Strategy for RA, Study Finds

      Results of a recent study showed that biological therapy regimens, such as Enbrel (etanercept), Humira (adalimumab), ‎Remicade (infliximab), ‎Simponi (golimumab), or ‎Cimzia (certolizumab), are less ... Read more
    • May 23, 2017May 23, 2017

      Kevzara Approved by FDA for Treatment of RA in Adults Who Don’t Respond to DMARDs

      Kevzara (sarilumab) was approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with moderate to severely active rheumatoid ... Read more
    Diplomat Pharmacy Begins Dispensing Kevzara to Treat Rheumatoid Arthritis
    June 12, 2017June 12, 2017

    Diplomat Pharmacy Begins Dispensing Kevzara to Treat Rheumatoid Arthritis

    News, rheumatoid arthritis
    Diplomat Pharmacy has begun filling prescriptions for Kevzara (sarilumab) for patients with moderate to severe rheumatoid arthritis (RA). The announcement comes after the U.S. Food and Drug Administration approving the therapy in ... Read more
    Filgotinib Improves RA Patient Outcomes When Methotrexate Is Inadequate, Study Suggests
    June 7, 2017June 7, 2017

    Filgotinib Improves RA Patient Outcomes When Methotrexate Is Inadequate, Study Suggests

    News, rheumatoid arthritis
    Active rheumatoid arthritis (RA) patients whose response to methotrexate (MTX) therapy was insufficient showed improvement when MTX was combined with filgotinib, an investigational JAK–1 inhibitor, according to results of a ... Read more
    EMA Accepts Humira and Remicade Biosimilars for Regulatory Review
    June 5, 2017June 5, 2017

    EMA Accepts Humira and Remicade Biosimilars for Regulatory Review

    News
    The European Medicines Agency (EMA) has accepted a marketing authorization application from generic pharmaceuticals developer Sandoz for the review of biosimilars for AbbVie’s Humira (adalimumab) and Janssen’s Remicade (infliximab), used in the treatment ... Read more
    DMARDs Triple Therapy Provides Better Cost-Effective First Line Strategy for RA, Study Finds
    June 2, 2017June 2, 2017

    DMARDs Triple Therapy Provides Better Cost-Effective First Line Strategy for RA, Study Finds

    News, rheumatoid arthritis
    Results of a recent study showed that biological therapy regimens, such as Enbrel (etanercept), Humira (adalimumab), ‎Remicade (infliximab), ‎Simponi (golimumab), or ‎Cimzia (certolizumab), are less cost-effective compared to DMARD combination ... Read more
    Kevzara Approved by FDA for Treatment of RA in Adults Who Don’t Respond to DMARDs
    May 23, 2017May 23, 2017

    Kevzara Approved by FDA for Treatment of RA in Adults Who Don’t Respond to DMARDs

    News, rheumatoid arthritis
    Kevzara (sarilumab) was approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with moderate to severely active rheumatoid arthritis (RA) who have not ... Read more
    Learning Sessions Help Rheumatologists Take Better Care of RA Patients, Study Says
    May 22, 2017May 22, 2017

    Learning Sessions Help Rheumatologists Take Better Care of RA Patients, Study Says

    News
    Group-based quality improvement sessions, based on the recommended “treat to target” (TTT) approach, can help rheumatologists improve the quality of their care for rheumatoid arthritis (RA) patients, a recent ... Read more
    Potential Treatment Sirukumab Up Before FDA and EMA with High Expectations, J&J Reports
    May 19, 2017May 19, 2017

    Potential Treatment Sirukumab Up Before FDA and EMA with High Expectations, J&J Reports

    News, rheumatoid arthritis
    A potential treatment for moderate-to-severe rheumatoid arthritis, sirukumab, is under consideration by the U.S. Food and Drug Administration for approval, with the application supported by results from five Phase 3 clinical ... Read more
    Can-Fite Files Clinical Trial Application in Canada for Piclidenoson to Treat RA
    May 17, 2017May 17, 2017

    Can-Fite Files Clinical Trial Application in Canada for Piclidenoson to Treat RA

    News
    Can-Fite BioPharma has filed a clinical trial application (CTA) with Health Canada for piclidenoson (CF101) as a treatment for rheumatoid arthritis (RA). Piclidenoson is an orally bioavailable drug with a favorable ... Read more
    Biosimilar CT-P13 Can Safely Replace Much More Expensive Remicade as RA Treatment, Study Finds
    May 15, 2017May 15, 2017

    Biosimilar CT-P13 Can Safely Replace Much More Expensive Remicade as RA Treatment, Study Finds

    News
    Rheumatoid arthritis (RA) patients taking Remicade (infliximab) can safely switch to CT-P13 (developed by Celltrion) — a much cheaper biosimilar of Remicade — according to a Norwegian study published in The Lancet. ... Read more
    Researchers Uncover Gene Variations Linked to RA, Other Immune Diseases
    May 12, 2017September 22, 2017

    Researchers Uncover Gene Variations Linked to RA, Other Immune Diseases

    News, rheumatoid arthritis
    A large-scale genetic study, in combination with information from electronic health records (EHRs), identified new human leukocyte antigen (HLA) associations with several immune conditions, including rheumatoid arthritis and multiple ... Read more

    Posts navigation

    Older posts

    Never miss another RA update.

    * indicates required

    Rheumatoid Arthritis News

    BioNews Services, LLC
    1601 Market St.
    Suite 20A105
    Philadelphia, PA 19103
    Email: [email protected]
    Phone: 1-800-936-1363

    Recent Posts

    • Diplomat selling Kevzara

      Diplomat Pharmacy Begins Dispensing Kevzara to Treat Rheumatoid Arthritis

      June 12, 2017

    • Filgotinib Improves RA Patient Outcomes When Methotrexate Is Inadequate, Study Suggests

      June 7, 2017

    • Truxima, a biosimilar of rituximab

      EMA Accepts Humira and Remicade Biosimilars for Regulatory Review

      June 5, 2017

    • triple therapy

      DMARDs Triple Therapy Provides Better Cost-Effective First Line Strategy for RA, Study Finds

      June 2, 2017

    • About Us
    • Contact Us
    • Terms of Service
    • Privacy Policy

    Disclaimer:

    Rheumatoid Arthritis News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
    Copyright © 2013-2020 All rights reserved.

      Pin It on Pinterest

      We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. We never use your cookies for creepy ad retargeting that follows you around the web. OkRead more